NO20061876L - Optimalisert uttrykking av HPV45-L1 i gjaer - Google Patents

Optimalisert uttrykking av HPV45-L1 i gjaer

Info

Publication number
NO20061876L
NO20061876L NO20061876A NO20061876A NO20061876L NO 20061876 L NO20061876 L NO 20061876L NO 20061876 A NO20061876 A NO 20061876A NO 20061876 A NO20061876 A NO 20061876A NO 20061876 L NO20061876 L NO 20061876L
Authority
NO
Norway
Prior art keywords
hpv45
protein
vlps
vaccines
prepare
Prior art date
Application number
NO20061876A
Other languages
English (en)
Other versions
NO339932B1 (no
Inventor
Kathrin Ute Jansen
Loren D Schultz
Janine Bryan
Michelle K Brownlow
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20061876L publication Critical patent/NO20061876L/no
Publication of NO339932B1 publication Critical patent/NO339932B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Syntetiske DNA-molekyler som koder for HPV45-LI-proteinet blir tilveiebrakt. Spesifikt tilveiebringer forehggende oppfinnelse polynukleotider som koder for HPV45-L1 protein, der nevnte polynukleotider har blitt kodonoptimahsert for høynivåuttykking i en gjærcelle. De syntetiske molekylene kan bli benyttet til å fremstille HPV45-viruslignende partikler (VLPer) og til å fremstille vaksiner og farmasøytiske preparater som omfatter HPV45-VLPene. Vaksinene ifølge foreliggende oppfirmelse tilveiebringer effektiv immunprofylakse mot papillomavirusinfeksjon via nøyfraliserende antistoff og cellemediert immunitet.
NO20061876A 2003-09-29 2006-04-28 Nukleinsyremolekyl som koder for et HPV45-L1-protein, vektor som omfatter nukleinsyremolekylet, vertscelle som omfatter vektoren, samt en fremgangsmåte for fremstilling av HPV45-L1-viruslignende partikler (VLPer) i gjær og en fremgangsmåte for å fremstille en vaksine for behandling eller forebygging av HPV infeksjoner. NO339932B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (2)

Publication Number Publication Date
NO20061876L true NO20061876L (no) 2006-04-28
NO339932B1 NO339932B1 (no) 2017-02-20

Family

ID=34421558

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20061876A NO339932B1 (no) 2003-09-29 2006-04-28 Nukleinsyremolekyl som koder for et HPV45-L1-protein, vektor som omfatter nukleinsyremolekylet, vertscelle som omfatter vektoren, samt en fremgangsmåte for fremstilling av HPV45-L1-viruslignende partikler (VLPer) i gjær og en fremgangsmåte for å fremstille en vaksine for behandling eller forebygging av HPV infeksjoner.
NO2017012C NO2017012I1 (no) 2003-09-29 2017-04-05 HPV 45 L1 protein
NO2022051C NO2022051I1 (no) 2003-09-29 2022-11-30 HPV 45L1 protein - forlengelse SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2017012C NO2017012I1 (no) 2003-09-29 2017-04-05 HPV 45 L1 protein
NO2022051C NO2022051I1 (no) 2003-09-29 2022-11-30 HPV 45L1 protein - forlengelse SPC

Country Status (33)

Country Link
US (2) US7250170B2 (no)
EP (1) EP1673106B1 (no)
JP (4) JP5451960B2 (no)
KR (1) KR101165278B1 (no)
CN (1) CN1859923B (no)
AR (2) AR045804A1 (no)
AT (1) ATE435029T1 (no)
AU (1) AU2004277934B2 (no)
BE (1) BE2015C072I2 (no)
BR (1) BRPI0414845B8 (no)
CA (1) CA2539168C (no)
CY (2) CY1110525T1 (no)
DE (1) DE602004021828D1 (no)
DK (1) DK1673106T3 (no)
ES (1) ES2327530T3 (no)
FR (1) FR15C0083I2 (no)
HU (1) HUS1500063I1 (no)
IL (1) IL174458A (no)
IS (1) IS2694B (no)
LT (2) LTC1673106I2 (no)
LU (1) LU92902I2 (no)
MX (1) MXPA06003457A (no)
MY (1) MY140664A (no)
NL (1) NL300776I2 (no)
NO (3) NO339932B1 (no)
NZ (1) NZ545834A (no)
PL (1) PL1673106T3 (no)
PT (1) PT1673106E (no)
RU (1) RU2360001C2 (no)
SI (1) SI1673106T1 (no)
TW (1) TWI350853B (no)
WO (1) WO2005032586A1 (no)
ZA (1) ZA200601961B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
DK1730175T3 (da) * 2004-03-24 2010-08-23 Merck Sharp & Dohme Geoptimaliseerde expressie van HPV 52 L1 in gist
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AU2006239422A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
MX2010005699A (es) 2007-11-23 2010-09-14 Shanghai Zerun Biotechnology C Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
BRPI0924981B1 (pt) 2009-06-19 2022-02-08 Eyegene Inc Composição de vacina para câncer cervical
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
BR112013032338B1 (pt) 2011-06-15 2021-04-20 Posvax Co., Ltd método para melhorar o rendimento de produção para proteína l1 do papilomavírus humano
KR102049988B1 (ko) 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
BR112017004181A2 (pt) * 2014-09-11 2017-12-05 Cadila Healthcare Ltd ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
IL295234A (en) 2020-02-14 2022-10-01 Merck Sharp & Dohme Llc HPV vaccine
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
WO2023023152A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ336696A3 (en) * 1994-05-16 1997-07-16 Merck & Co Inc Isolated and purified proteins of papillomavirus and process for preparing thereof
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DK0969862T3 (da) 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
AU734761B2 (en) * 1997-05-27 2001-06-21 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
CA2296067C (en) 1997-07-09 2008-10-07 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
WO2000009157A1 (en) * 1998-08-14 2000-02-24 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
WO2000039151A1 (en) * 1998-12-23 2000-07-06 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
DE60016765T2 (de) * 1999-08-25 2005-11-24 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
HUP0300745A3 (en) 2000-07-21 2010-01-28 Glaxo Group Ltd Codon-optimized papilloma virus sequences
WO2003068933A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE546529T1 (de) 2003-03-24 2012-03-15 Merck Sharp & Dohme Optimierte expression von hpv 31 l1 in hefe

Also Published As

Publication number Publication date
KR101165278B1 (ko) 2012-07-23
ES2327530T3 (es) 2009-10-30
CN1859923B (zh) 2012-09-05
WO2005032586A1 (en) 2005-04-14
DK1673106T3 (da) 2009-11-09
LTC1673106I2 (lt) 2017-05-10
BRPI0414845B1 (pt) 2020-10-13
BE2015C072I2 (no) 2023-12-14
US20080138361A1 (en) 2008-06-12
CY2015050I2 (el) 2016-06-22
TW200521233A (en) 2005-07-01
KR20070029628A (ko) 2007-03-14
MY140664A (en) 2010-01-15
BRPI0414845B8 (pt) 2021-06-15
US7250170B2 (en) 2007-07-31
CA2539168C (en) 2011-05-31
IL174458A0 (en) 2006-08-01
CY2015050I1 (el) 2016-06-22
AU2004277934A1 (en) 2005-04-14
US20060240040A1 (en) 2006-10-26
ZA200601961B (en) 2007-05-30
FR15C0083I2 (fr) 2016-11-25
PT1673106E (pt) 2009-09-22
EP1673106A1 (en) 2006-06-28
JP2016136947A (ja) 2016-08-04
NO2017012I1 (no) 2017-04-05
ATE435029T1 (de) 2009-07-15
JP2011152137A (ja) 2011-08-11
DE602004021828D1 (de) 2009-08-13
FR15C0083I1 (fr) 2016-08-01
JP2014221052A (ja) 2014-11-27
AU2004277934B2 (en) 2009-09-17
JP5451960B2 (ja) 2014-03-26
SI1673106T1 (sl) 2009-12-31
RU2360001C2 (ru) 2009-06-27
NZ545834A (en) 2009-02-28
BRPI0414845A (pt) 2006-11-21
EP1673106B1 (en) 2009-07-01
NO339932B1 (no) 2017-02-20
IS8362A (is) 2006-03-20
CN1859923A (zh) 2006-11-08
LTPA2015049I1 (lt) 2016-01-11
AR045804A1 (es) 2005-11-16
CA2539168A1 (en) 2005-04-14
CY1110525T1 (el) 2015-04-29
TWI350853B (en) 2011-10-21
LU92902I2 (fr) 2016-03-08
IS2694B (is) 2010-11-15
MXPA06003457A (es) 2006-06-05
RU2006114701A (ru) 2007-11-10
AR077396A2 (es) 2011-08-24
US7482015B2 (en) 2009-01-27
NL300776I1 (no) 2015-12-29
IL174458A (en) 2014-06-30
NL300776I2 (no) 2015-12-29
HUS1500063I1 (hu) 2016-02-29
PL1673106T3 (pl) 2009-12-31
NO2022051I1 (no) 2022-11-30
JP2007507207A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
NO20061876L (no) Optimalisert uttrykking av HPV45-L1 i gjaer
NO20062674L (no) Optimalisert uttrykking av HPV58-L1 i gjaer
NO2018010I1 (no) HPV 31 L1 protein
NO20064815L (no) Optimalisert uttrykking av HPV 52-L1 i gjaer
WO2007066334A9 (en) Improved influenza vaccine
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004084939A8 (en) Hiv-peptide-carrier-conjugates
WO2001014416A3 (en) Synthetic papillomavirus genes optimized for expression in human cells
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
WO2005034841A3 (en) Anthrax vaccine
MY138895A (en) Optimized expression of hpv 31 l1 in yeast
TH108752B (th) การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์
WO2006114273A3 (en) Vaccine
TW200716169A (en) Vaccine

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: HPV 45 L1 PROTEIN; NAT. REG. NO/DATE: EU/1/15/1007/001-3 20150610; FIRST REG. NO/DATE: EU/1/15/1007/1001-3 20150610

Spc suppl protection certif: 2017012

Filing date: 20170405

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: HPV 45 L1 PROTEIN; NAT. REG. NO/DATE: EU/1/15/1007/001-3 20150610; FIRST REG. NO/DATE: EU/1/15/1007/1001-3 20150612

Spc suppl protection certif: 2017012

Filing date: 20170405

Extension date: 20290924

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP & DOHME LLC, US

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: HPV 45L1 PROTEIN - FORLENGELSE SPC; REG. NO/DATE: EU/1/15/1007/001-3 20150610

Spc suppl protection certif: 2022051

Filing date: 20221130